Figure 5. IT treatment with CMP-001 enhances T cell and dendritic cell infiltration into injected tumor-associated draining lymph nodes and A20 tumors.

A, Representative immunohistochemistry images from injected tumor sections stained for CD3 (data is from one experiment; n=4 tumors per group). B, Treatment schema of Balb/c mice primed and then implanted on both flanks with A20 B lymphoma cells, followed by unilateral IT saline or CMP-001 and IP anti-PD-1 or isotype control. Both tumors (noninjected and injected) and their corresponding draining inguinal lymph node were harvested 9 days after the first IT treatment and analyzed by flow cytometry. The number of CD45+ cells (C-D) and T cells (E-F) present per draining lymph node or per gram of A20 tumor (noninjected or injected; data is from 2 replicate experiments; n=5–8 tumors or 5–12 draining lymph nodes per group). Data were analyzed by one-way (C-D) or two-way (E-F) ANOVA with Dunnett’s multiple comparisons test; *P<0.05, **P<0.01; ****P<0.0001.